Datopotamab deruxtecan for breast cancer with brain spread
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that has spread to the brain (at least one brain tumor that is 1 cm or larger and has not been treated with radiation, or has grown after treatment).
- Your cancer type is HER2-negative (a specific kind of breast cancer).
- You are at least 18 years old and able to do daily activities (ECOG score 0-2).
- You have not had a major surgery in the last 4 weeks, and you have recovered from side effects of past treatments.
- Your heart function is normal (EF 50% or more), and your blood and kidney tests are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted cancer drug (T-DXd) with precise radiation to the brain for people with HER2-positive breast cancer that has spread to the brain. It aims to see if this combination can better control the brain tumors while being safe.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
This trial tests a new combination of targeted drugs for HER2-positive breast cancer that has spread to the brain. You might be able to join if you have brain metastases and are either newly diagnosed or have had prior brain radiation.
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
This trial studies Dato-DXd (an antibody-drug medicine) in people with triple-negative breast cancer that has spread to the brain. It aims to see how well it controls brain tumors when they are newly found or growing after other treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.